INDV
Indivior Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
36.89
▼ 0.89 (2.36%)
MARKET · —
Price
Open
37.78
Prev close
37.78
Day high
38.52
Day low
36.72
Volume
1.92M
Market cap
—
P/E (TTM)
—
52W range
22.22 – 42.81
Trailing performance
Returnvs SPY
1W
-5.49%
-4.1%
1M
-8.99%
-12.7%
3M
-1.58%
-4.7%
6M
+8.79%
-2.3%
YTD
+2.76%
-9.5%
1Y
+52.67%
+32.7%
3Y
+61.78%
-12.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
38.51
-4.20% from price
SMA 20
38.82
-5.04% from price
SMA 50
39.56
-6.80% from price
SMA 100
37.43
-1.45% from price
SMA 200
35.41
+4.12% from price
EMA 12
38.49
-4.15% from price
EMA 26
38.90
-5.17% from price
EMA 50
38.78
-4.88% from price
RSI (14)
37.1
Neutral
MACD (12,26,9)
-0.41
Hist -0.13
ATR (14)
1.41
3.81% of price
Realised vol 30D
35.6%
Annualised
Bollinger upper
41.05
20, 2σ
Bollinger lower
36.60
20, 2σ
50 / 200 cross
Golden
39.56 vs 35.41
Trend bias
Above 200
+4.12%
Risk profile
Beta vs SPY
0.42
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
35.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-21.4%
Peak to trough
Max drawdown 5Y
-85.5%
Peak to trough
ATR 14
1.41
3.81% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
Simply Wall St. · 15h ago
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Zacks · 1d ago
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Zacks · 1d ago
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"
Zacks · 11d ago
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Zacks · 18d ago
Indivior Q2 Earnings Call Highlights
MarketBeat · 19d ago
Sector Update: Healthcare Stocks Rise Pre-Bell Monday
MT Newswires · 19d ago
Supernus jumps premarket on merger deal; GameStop drops
Investing.com · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.